The trial evaluating MediPrint™ Ophthalmics’ LLT-BMT1 – a drug-eluting contact lens being developed to treat glaucoma has been completed, showing safe and tolerable results as well as reduction of hyperaemia.
Check the article out here: Drug-eluting contact lens shows potential in first-in-human study (europeanpharmaceuticalreview.com)